Ra. Clarke et al., ABSENCE OF ATM TRUNCATIONS IN PATIENTS WITH SEVERE ACUTE RADIATION REACTIONS, International journal of radiation oncology, biology, physics, 41(5), 1998, pp. 1021-1027
Citations number
29
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
Purpose: Severe acute toxicity limits the effective use of radiotherap
y in patients who are radiosensitive, and it is not usually possible t
o identify these radiohypersensitive (R-H) individuals before treatmen
t commences. Five such R-H patients were detected over a 3-year period
. We undertook this study to determine whether the severe acute radioh
ypersensitivity of these five individuals showed any correlation with
cellular and molecular parameters known to be abnormal in radiosensiti
vity-related syndromes such as ataxia-telangiectasia (A-T), Methods an
d Materials: Lymphoblastoid cells were isolated from fresh blood from
the 5 R-H individuals who had previously demonstrated clinical R-H at
least 9 months prior to sampling. Lymphoblastoid cell lines (LCLs) wer
e established to determine the extent of postradiation chromosomal abe
rrations, cell cycle delay, cell proliferation, and tumor suppressor p
53 protein stabilization. The polymerase chain reaction (PCR) and prot
ein truncation (PTT) assays were used to test for the possibility of m
utations in the gene mutated in A-T, termed ATM, Results: LCLs derived
from R-H subjects retained a significantly higher degree of radiation
-induced chromosomal aberrations when compared to normal control LCLs,
p53 stabilization by ionizing radiation appeared normal in all but on
e R-H subject. There was no evidence of A-T gene truncation mutations
in any of the R-H subjects tested. Conclusions: All R-H subjects in th
is study had their cellular radiosensitivity confirmed by the chromoso
mal aberration assay. Delayed p53 stabilization at 4 hours postirradia
tion in one R-H subject suggested that different etiologies may apply
in the radiohypersensitivity investigated in this study. (C) 1998 Else
vier Science Inc.